MA54386B1 - Modulateurs de trex1 - Google Patents

Modulateurs de trex1

Info

Publication number
MA54386B1
MA54386B1 MA54386A MA54386A MA54386B1 MA 54386 B1 MA54386 B1 MA 54386B1 MA 54386 A MA54386 A MA 54386A MA 54386 A MA54386 A MA 54386A MA 54386 B1 MA54386 B1 MA 54386B1
Authority
MA
Morocco
Prior art keywords
trex1
modulators
salts
compounds
variety
Prior art date
Application number
MA54386A
Other languages
English (en)
Other versions
MA54386A (fr
Inventor
Victor Gehling
Avinash Khanna
Anna Gardberg
Julian Levell
Jonathan Wilson
Kennedy Taveras
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of MA54386A publication Critical patent/MA54386A/fr
Publication of MA54386B1 publication Critical patent/MA54386B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Burglar Alarm Systems (AREA)

Abstract

L'invention concerne des composés de formule (i) : ainsi que des sels et des compositions pharmaceutiquement acceptables de ceux-ci, qui sont utiles pour le traitement d'une variété d'états pathologiques associés à trex1.
MA54386A 2018-12-06 2019-12-06 Modulateurs de trex1 MA54386B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776031P 2018-12-06 2018-12-06
PCT/US2019/064825 WO2020118133A1 (fr) 2018-12-06 2019-12-06 Modulateurs de trex1

Publications (2)

Publication Number Publication Date
MA54386A MA54386A (fr) 2021-10-13
MA54386B1 true MA54386B1 (fr) 2023-08-31

Family

ID=69024702

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54386A MA54386B1 (fr) 2018-12-06 2019-12-06 Modulateurs de trex1

Country Status (30)

Country Link
US (2) US12172990B2 (fr)
EP (1) EP3891145B1 (fr)
JP (1) JP7471297B2 (fr)
KR (1) KR20210102310A (fr)
CN (1) CN113396149B (fr)
AU (1) AU2019395005B2 (fr)
BR (1) BR112021010919A2 (fr)
CA (1) CA3122093A1 (fr)
CL (1) CL2021001461A1 (fr)
CO (1) CO2021008816A2 (fr)
CY (1) CY1126082T1 (fr)
DK (1) DK3891145T3 (fr)
EA (1) EA202191519A1 (fr)
ES (1) ES2949999T3 (fr)
FI (1) FI3891145T3 (fr)
HR (1) HRP20230701T1 (fr)
HU (1) HUE062866T2 (fr)
IL (1) IL283672B2 (fr)
LT (1) LT3891145T (fr)
MA (1) MA54386B1 (fr)
MX (1) MX2021006695A (fr)
MY (1) MY207276A (fr)
PE (1) PE20212070A1 (fr)
PH (1) PH12021551317A1 (fr)
PL (1) PL3891145T3 (fr)
PT (1) PT3891145T (fr)
RS (1) RS64336B1 (fr)
SG (1) SG11202105772SA (fr)
SI (1) SI3891145T1 (fr)
WO (1) WO2020118133A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210102310A (ko) 2018-12-06 2021-08-19 콘스텔레이션 파마슈티칼스, 인크. Trex1의 조절인자
EP4003985A1 (fr) * 2019-07-23 2022-06-01 Constellation Pharmaceuticals, Inc. Modulateurs de trex1
CA3177376A1 (fr) * 2020-05-01 2021-11-04 Julian R. Levell Modulateurs de trex1
US20230278957A1 (en) * 2020-08-04 2023-09-07 Wake Forest University Health Sciences Trex1 inhibitors and uses thereof
AR125448A1 (es) * 2021-04-26 2023-07-19 Constellation Pharmaceuticals Inc Moduladores de trex1
MX2023013045A (es) * 2021-05-05 2024-01-19 Constellation Pharmaceuticals Inc Moduladores de exonucleasa i de tres reparaciones principales (trex1).
WO2023137030A1 (fr) * 2022-01-11 2023-07-20 Constellation Pharmaceuticals, Inc. Modulateurs de trex1
JP2025508714A (ja) * 2022-02-16 2025-04-10 デューク ストリート バイオ リミテッド 医薬化合物
WO2023250439A1 (fr) * 2022-06-22 2023-12-28 Tempest Therapeutics, Inc. Inhibiteurs de trex1 et leurs utilisations
WO2024061300A1 (fr) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibiteurs de trex1 et utilisations associées

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000048I1 (de) 2001-10-26 2010-04-08 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
EP1654249A1 (fr) 2003-08-07 2006-05-10 Pharmacia & Upjohn Company LLC Derives de pyrimidine anthelminthiques et insecticides
MX2008002014A (es) 2005-08-15 2008-03-27 Hoffmann La Roche Derivados de piperidina y piperazina como antagonistas de p2x3.
US20100152209A1 (en) 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
WO2008033564A1 (fr) 2006-09-15 2008-03-20 Hydra Biosciences Inc. Composés permettant de moduler la fonction du trpv3
WO2008113006A1 (fr) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Procédés d'utilisation de composés à base de quinolinone dans le traitement des maladies ou des affections associées aux canaux sodiques
WO2009106561A1 (fr) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Composés pyrazines pour le traitement de troubles apparentés à gpr119
JP5559156B2 (ja) 2008-06-02 2014-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ３，４−ジヒドロピリミジンｔｒｐａ１アンタゴニスト
AU2009279616A1 (en) 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
BR112012007349A2 (pt) 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2012016133A2 (fr) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
US9221826B2 (en) 2011-03-17 2015-12-29 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2012151567A1 (fr) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Composés de pyrimidinone et méthodes de prévention et de traitement de la grippe
JP2014237589A (ja) 2011-09-28 2014-12-18 日本曹達株式会社 環状アミン化合物および有害生物防除剤
HK1211289A1 (en) 2012-08-06 2016-05-20 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20160264536A1 (en) 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2014365823B2 (en) 2013-12-16 2019-05-02 Abs Development 1, Inc. P2X3 and/or P2X2/3 compounds and methods
WO2016183741A1 (fr) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Composés de pyrimidinone amide en tant qu'inhibiteurs de pde2
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
US20210246122A1 (en) 2018-06-22 2021-08-12 Aduro Biotech, Inc. Triazine Compounds and Uses Thereof
KR20210102310A (ko) 2018-12-06 2021-08-19 콘스텔레이션 파마슈티칼스, 인크. Trex1의 조절인자
CN114341125A (zh) 2019-05-02 2022-04-12 星座制药公司 Trex1调节剂
EP4003985A1 (fr) 2019-07-23 2022-06-01 Constellation Pharmaceuticals, Inc. Modulateurs de trex1

Also Published As

Publication number Publication date
LT3891145T (lt) 2023-08-10
KR20210102310A (ko) 2021-08-19
AU2019395005B2 (en) 2025-06-05
IL283672B2 (en) 2024-10-01
FI3891145T3 (fi) 2023-07-18
CA3122093A1 (fr) 2020-06-11
CL2021001461A1 (es) 2021-12-17
MY207276A (en) 2025-02-13
US12172990B2 (en) 2024-12-24
ES2949999T3 (es) 2023-10-04
CN113396149A (zh) 2021-09-14
EA202191519A1 (ru) 2021-10-27
JP2022510431A (ja) 2022-01-26
US20220017502A1 (en) 2022-01-20
MX2021006695A (es) 2021-09-23
EP3891145B1 (fr) 2023-04-12
AU2019395005A1 (en) 2021-06-17
PT3891145T (pt) 2023-07-18
JP7471297B2 (ja) 2024-04-19
EP3891145A1 (fr) 2021-10-13
SG11202105772SA (en) 2021-06-29
RS64336B1 (sr) 2023-08-31
PE20212070A1 (es) 2021-10-26
BR112021010919A2 (pt) 2021-08-24
CO2021008816A2 (es) 2021-07-19
HUE062866T2 (hu) 2023-12-28
CN113396149B (zh) 2024-07-02
US20250136588A1 (en) 2025-05-01
CY1126082T1 (el) 2023-11-15
DK3891145T3 (da) 2023-07-24
IL283672B1 (en) 2024-06-01
SI3891145T1 (sl) 2023-11-30
WO2020118133A1 (fr) 2020-06-11
HRP20230701T1 (hr) 2023-10-13
MA54386A (fr) 2021-10-13
PL3891145T3 (pl) 2023-08-07
IL283672A (en) 2021-07-29
PH12021551317A1 (en) 2022-05-16

Similar Documents

Publication Publication Date Title
MA51530B1 (fr) Composés cycliques fondus
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA35285B1 (fr) Indazoles
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA67105B1 (fr) Agonistes inverses de pparg et leurs utilisations
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA38661A1 (fr) Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA54133A (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA40290A1 (fr) Agents immunorégulateurs
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar